Bicycle Therapeutics (BCYC) Cash from Investing Activities (2018 - 2026)
Bicycle Therapeutics' (BCYC) quarterly Cash from Investing Activities came in at -$265000.0 in Q2 2026, up 46.79% YoY from -$180533.5 in Q2 2025, and up 62.83% on a QoQ basis from -$713000.0 in Q1 2026.
Powered by 
Analysis
Bicycle Therapeutics (BCYC) Cash from Investing Activities (2018 - 2026) Analysis & Trends
Bicycle Therapeutics (BCYC) has 9 years of Cash from Investing Activities data on file, last reported at -$265000.0 in Q2 2026.
- Quarterly Cash from Investing Activities rose 46.79% year-over-year to -$265000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$2.2 million (down 16.85% YoY) and the FY2025 annual result came in at -$2.4 million, down 90.28% from the prior year.
- Cash from Investing Activities climbed to -$265000.0 in Q2 2026, from -$713000.0 in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of -$12000.0 in Q1 2024 to a low of -$9.8 million in Q2 2022.
- A 5-year average of -$1.5 million and a median of -$538000.0 in 2023 frame the typical range for Cash from Investing Activities.
- Annual changes were most pronounced in 2022 — Cash from Investing Activities slumped 5630.41% — and 2024, when it jumped 99.43%.
- Tracing BCYC's Cash from Investing Activities over 5 years: stood at -$1.4 million in 2022, then jumped by 96.48% to -$51000.0 in 2023, then plunged by 621.57% to -$368000.0 in 2024, then sank by 55.98% to -$574000.0 in 2025, then jumped by 53.83% to -$265000.0 in 2026.
- The last three Cash from Investing Activities figures came in at -$265000.0 (Q2 2026), -$713000.0 (Q1 2026), and -$574000.0 (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 329.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -1.66 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | -49.35 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -363.46 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -229.72 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 24.51 Mn |
| 10 | Bicycle Therapeutics | 299.81 Mn | 299.81 Mn | - | -265,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -265,000.00 |
| Mar 31, 2026 | -713,000.00 |
| Dec 31, 2025 | -574,000.00 |
| Sep 30, 2025 | -674,000.00 |
| Jun 30, 2025 | -498,000.00 |
| Mar 31, 2025 | -604,000.00 |
| Dec 31, 2024 | -368,000.00 |
| Sep 30, 2024 | -435,000.00 |
| Jun 30, 2024 | -420,000.00 |
| Mar 31, 2024 | -12,000.00 |
| Dec 31, 2023 | -51,000.00 |
| Sep 30, 2023 | -502,000.00 |
| Jun 30, 2023 | -277,000.00 |
| Mar 31, 2023 | -2.10 Mn |
| Dec 31, 2022 | -1.45 Mn |
| Sep 30, 2022 | -2.98 Mn |
| Jun 30, 2022 | -9.80 Mn |
| Mar 31, 2022 | -4.76 Mn |
| Dec 31, 2021 | -1.07 Mn |
| Sep 30, 2021 | -169,000.00 |